MARKET

CORV

CORV

Correvio Pharma Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3760
-0.0120
-3.09%
Closed 19:42 04/01 EDT
OPEN
0.3850
PREV CLOSE
0.3880
HIGH
0.3870
LOW
0.3700
VOLUME
1.66M
TURNOVER
--
52 WEEK HIGH
3.210
52 WEEK LOW
0.2100
MARKET CAP
20.82M
P/E (TTM)
-0.4177
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CORV stock price target is 1.085 with a high estimate of 1.750 and a low estimate of 0.4200.

EPS

CORV News

More
  • Correvio Pharma (CORV) Reports Q4 Loss, Misses Revenue Estimates
  • Zacks · 2d ago
  • Correvio Reports Full Year 2019 Financial Results
  • PR Newswire · 2d ago
  • Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies CORV, TERP, IOTS, CBB
  • GlobeNewswire · 03/24 13:00
  • CORREVIO PHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Correvio Pharma Corp. - CORV
  • Business Wire · 03/21 01:05

Industry

Pharmaceuticals
-2.46%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About CORV

Correvio Pharma Corp is a Canada-based specialty pharmaceutical company. It provides brands that meet the needs of acute care physicians and patients. It develops, acquires and commercializes brands for the in-hospital, acute care market segment. The following is its portfolio of approved and marketed brands: Xydalba, for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP); Brinavess for the conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, as well as Esmocard and Esmocard Lyo, a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications. Its pipeline of product candidates includes Trevyent, a drug device combination that is designed to deliver treprostinil.
More

Webull offers kinds of Correvio Pharma Corp stock information, including NASDAQ:CORV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CORV stock news, and many more online research tools to help you make informed decisions.